DYOR! (Comments?)

Amazingly good news today I topped up on the news

RNS Number:9656R
Proteome Sciences PLC
12 November 2003



PROTEOME SCIENCES plc

PRESS RELEASE


Proteome Sciences Awarded Grant of US Patent For Diagnosis of Three Major
Cancers

Proteome Sciences plc ("Proteome Sciences"), is pleased to announce that it has
today been granted US Patent No. 6,645,465 entitled "Annexin Proteins and
Autoantibodies as Serum Markers for Cancer".

Annexins are a class of at least 12 different proteins with a putative role in
controlling cell signalling and metabolism. Elevation of certain annexins
correlates with various diseases. Work funded by Proteome Sciences led to the
discovery that anexins I and II are elevated in three major cancers, namely
lung, breast and oesophageal cancers. Significantly, it was possible to develop
a test that could detect antibodies to these proteins in the blood of patients
with tumours, but not in healthy individuals.

The granted patent includes claims to the use of annexins and antibodies to them
in the diagnosis of lung, breast and oesophageal cancers, which collectively
account for an estimated 400,000 new cases each year in the US, roughly 1
million worldwide. Proteome Sciences is actively pursuing partners to co-develop
new diagnostic and prognostic tests based on detection of annexin
autoantibodies, in line with its long-standing practice of partnering
activities.

Commenting on the announcement, Christopher Pearce, Chief Executive of Proteome
Sciences said :

"We are very pleased to see the grant of a key patent for an important class of
cancer biomarkers. This is the first of a series of patents to be granted from
our research in cancer and which underpins the value of our early programmes in
biomarker discovery. This allows us to secure strong commercial partnerships to
develop new diagnostic and prognostic assays for these important diseases where
diagnosis is often made too late for effective treatment and to accelerate the
development of therapeutic targets.


Using its ProteoSHOPTM tool box Proteome Sciences is focused to discover and
validate new biomarkers across a broad range of major diseases including
neurodegeneration, neuroscience, diabetes/obesity, cardiovascular disease and
cancer, which, together with its strong portfolio of existing intellectual
property, places us at the forefront of applied proteomics.".


- Ends -

Notice GNI topped up to the tune 1.3M shares on Friday/last week, that's confidence.

A :- Result of E.G.M.

B :- Dr G.W.Schmidt resigned ------------- Frankfurt facilities.

Agreement with Medical Research Council

Appears - to me - to be Very Positive to the extent I think everyone on the
tread should read it rgds aj

Directors Interest:-

Dr Sandra S.Steiner

Looks like this has started moving up again.

I am amazed there is such a lack of interest/few posts on this share as it is
a very interesting one.aj

Today + 1.00 / + 0 .51 per cent

No, I'm very interested and have posted such on numerous occassions!

Meant to post this while back. Its a good profile on PRM.

http://www.pharmaco-genomics.co.uk/admin/files/PGS040515.pdf

Has PRM peaked? Or has it further to go?

IMHO this has a lot further to run, credit lyonais upped it's stake this week and the directors have bought big style, also changed advisor, I think this is still early days and I'm adding more.

Dam dam dam, missed it, should of bought last night, thought it woul push down one last time, still I think will move to new highs 3 target or q1.

Mmmmhhhh - wondered whether to post as most investors hate to hear about negatives. So just a couple of thoughts in summary and dyor.

1. Check out the fundamentals - valuation vs sales vs future potential royalty income stream.

2. Primarily a diagnostics test development Company - check out the biggest diagnostic players/their turnovers/profits etc. To give you a start - look at Roche/Abbot and Axis Shield platforms/products and how they are sold. Whose platforms will PRM's tests go on to and what is average take? Plus latest in-vitro, simple urine/blood tests cost less than 3c per strip to produce. Work out the quantity of tests/likely royalty income stream should the strips replace some of the more complex assay test platforms used in labs. Did you know there are already simple blood test strips for detecting cancer? Further tests are then done to determine the specific type/location.

3. Why are PRM's diagnostic markers better than existing/others also being developed? At the end of the day the cost of the test/accuracy will determine sales/income levels. Also approval FDA/EU for in-vitro diagnostic systems are simple/fast compared to treatments/drug testing so lead time/patent benefits very limited. Generic/copying with marginally different assays/procedures a problem in diagnostic testing.

4. PRM has been hyped tremendously and often last pump before the decline (end of the push) is takeover rumours which have now surfaced.

In summary this Company is valued at some 250m - work out the number of tests that need to be sold and future royalty income stream to back up this valuation.

Having said all the above I should point out I bought in at under 40p and sold far too early so wtfdik and this could still go to 250 or higher. No position currently.

Good luck everyone.

Suggest today's rise is as a result of Shares making it one of their tips for 2004 (p22).

Rise was because of bse news in the States. Look at PTI first though, it's on the market testing dead carcasses!! PRM do a live test eventually, trouble with that though is the fact the animal can be infected an hour later?!

Hi, my 1st contribution here.

Made good profit on PRM !!! but sold far too soon ! about 140.

I like this format... its like ADVFN which I know.

ADVFN seems dead this weekend so I've joined here...

I'll be trying things...

Buy Proteome Sciences at 200p Argues Andrew Griffiths of The AIM &OFEX Newsletter [links to https://secure.redskyresearch.com/images/aim_ukanalyst_trial.html]

Proteome Sciences is a biotech fledgling that is becoming something of a darling among City life sciences analysts with the shares trebling last year. A hefty research tome from Evolution Beeson Gregory just before Christmas added to the intellectual firepower supporting the price.
To the uninitiated, Proteome might appear to be just another biotech hopeful with no profits and an inflated market capitalisation. Those with long memories will remember the company as Electrophoretics, one of the earliest AIM entrants, and one that always seemed to be promising a breakthrough tomorrow. But nearly a decade after its public company debut and with the same management in place, a positive consensus finally appears to be emerging among analysts about its potential.

Many believe this "technology rich" life sciences company can translate its commercial potential into big revenues, starting from next year, and the market looks like believing the story. Proteome is a significant player in the field of proteomics - the "next revolution in drug discovery" according to some - the analysis of proteins within a cell. The discipline identifies relevant genes and proteins as potential targets for drugs and for diagnostic tools, so producing a new way of identifying and targeting disease.

The technology has allowed the company to identify "biomarkers" within cells, which can be used to diagnose diseases. Proteome has licensing agreements for a stroke biomarker, which can identify whether a patient has suffered a stroke, and a TSE (transmissible spongiform encephalopathies) marker, which may be used to diagnose BSE ("mad cow disease") within cattle and CJD in humans. Each could generate significant royalty payments and the company has another ten markers in the offing. Evolution estimates that the world proteomics market is worth $1.5bn (800m) and is expected to grow at around 20% each year for the next five years.

As far as revenues go, the broker is forecasting sales of 700,000 for the current year, rising sharply to 2.9m in 2004. But it does not expect the company to break even until 2005. Fortunately, Proteome Sciences has the cash (more than 6m) to see it through until then.
Beyond 2005, Evolution expects annual revenues to snowball into tens of millions of pounds. The forecasts rather optimistically assume that each commercialised marker will be used to create a diagnostic product and a pharmaceutical, and that the company will license an average of 1.5 markers per year.
Whether all this is enough to justify a 228m market capitalisation is a moot point but Proteome appears to be making its best progress for a decade. Brokers believe the shares have further to go, which makes them an interesting speculation. Buy. Key Data


EPIC: PRM
Market: AIM
NMS: 10,000
Spread: 199p-201p
Market Cap: 228 million

Andrew Griffiths is managing editor of The AIM &OFEX Newsletter, which specialises in digging out fast growing shares from London's junior stockmarkets. Recent successful tips include Datacash up 252%, Fayrewood up 142%, and Epic Group, up 125%. For a two issue free trial click here [links to https://secure.redskyresearch.com/images/aim_ukanalyst_trial.html].

More good news
GRANT OF US CANCER PATENT FOR NEUROBLASTOMA AND GLIOMA IN BLOOD


http://www.uk-wire.com/cgi-bin/articles/200401260841586140U.html

Why has no one posted any messages for over a month? Have you all sold up and moved on?? New to the site and have found the messages interesting reading. Can not make my mind up whether to sell proteome now or hold on. I read one article recently that told readers to get out of proteome fast but other forecasters seem positive. Its gone down to 206p today. Be intersted to know what anyone elses thoughts are.

after the all the recent falls to low of 139p today ...level 2 is now showing upward movement by the mm's ... recent rns by co no reason for price fall .. now around 143p